Abstract:Background: P38α is a ubiquitous protein kinase, which plays diverse roles in cancers. Surprisingly, P38α functions vary markedly in different cancers (e.g., cancer suppressor vs cancer promoter). However, there is no report on the expression of P38α, the family's most important member, in pancreatic ductal adenocarcinoma (PDAC) and its association with clinicoathological parameters and patients' prognosis. Materials and methods: We retrospectively analyzed 152 patients who underwent surgery and were pathologically diagnosed with PDAC from September 2013 to September 2015. We used immunohistochemistry to detect P38α expression in tumor and adjacent normal tissues. The significance of the association between P38α and clinicopathological parameters was evaluated using the χ² test and t tests. The Kaplan-Meier method was used to assess the association between P38α expression and preoperative carbohydrate antigen 19-9 (CA19-9) levels and patients' overall survival. The Cox regression model was used to analyze the association between clinicopathological parameters, P38α and preoperative CA19-9 levels, and prognosis. Statistical significance was defined as P < 0.05. Results: P38α was expressed in 63.16% tumor tissues of PDAC, which was significantly higher compared with the adjacent normal tissues (26.32%, P < 0.001). High expression of P38α was associated with patients' histological grade (P = 0.013), lymphatic metastasis (P = 0.025) and TNM stage (P = 0.048). The median survival time of the P38α-high group was 9.2 months, which was shorter compared with that of the P38α-low group (17.3 months, P = 0.011). The median survival time of the CA19-9 > 43.63 group was 11.1 months shorter than that of the CA19-9 < 43.63 group (24.8 months, P < 0.001). The Cox regression model revealed that age (P = 0.003), lymphatic invasion (P = 0.015), TNM stage (P = 0.003), histological grade (P < 0.001), preoperative CA19-9 (P = 0.049), and P38α expression (P = 0.008) were statistically significant independent risk factors affecting prognosis. Specifically, overall survival was 28.4 months in the P38α-low and CA19-9 < 43.63 groups, 16.3 months in the P38α-high or CA19-9 > 43.63 groups, and 9.7 months in the P38α-high and CA19-9 > 43.63 groups (P < 0.001). Conclusions: High expression of P38α was significantly associated with histological grade, lymphatic metastasis, TNM stage and prognosis in patients with PDAC. P38α and preoperative CA19-9 levels were independent risk factors affecting the prognosis of PDAC patients. High expression of p38α and preoperative carbohydrate antigen 19-9 indicate poor prognosis in patients with PDAC.

Clinical impact and prognostic value of CD 147 and MMP-7 expression in patients with pancreatic ductal adenocarcinoma

Prognostic Value of Programmed Cell Death Protein 1 Expression on CD8+ T Lymphocytes in Pancreatic Cancer

Prognostic Significance of Matrix Metalloproteinase 7 Immunohistochemical Expression in Colorectal Cancer: a Meta-Analysis.

Expression of CD147 and Matrix Metalloproteinase-11 in Colorectal Cancer and Their Relationship to Clinicopathological Features.

Comparison of Tumor Markers for Predicting Disease-Free Survival in Surgically Resected Pancreatic Neuroendocrine Tumors

High Expression of P38α and Preoperative Carbohydrate Antigen 19-9 Indicate Poor Prognosis in Patients with Pancreatic Ductal Adenocarcinoma

CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.

Overexpressions of DLL4 and CD105 Are Associated with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma

The Expressions of CD151 and MMP-7 in Lung Adenocarcinoma Tissues and Their Clinical Significance

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review

Expressions of Matrix Metalloproteinase-2 and -9 in Pancreatic Carcinoma and Its Significance

Effect of CD74 on the Prognosis of Patients with Resectable Pancreatic Cancer

Expression of CD151 c-Met, integrin alpha 3, alpha 6 and the prognostic significance in pancreatic ductal adenocarcinoma

Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma.

Identification of Genomic Alterations and Associated Transcriptomic Profiling Reveal the Prognostic Significance of MMP14 and PKM2 in Patients with Pancreatic Cancer.

Integrated Expression Profiles Analysis Reveals Novel Predictive Biomarker in Pancreatic Ductal Adenocarcinoma

MMP11 as a prognostic biomarker correlated with immune infiltrates in pancreatic adenocarcinoma

Prognostic and Predictive Value of a Five-Molecule Panel in Resected Pancreatic Ductal Adenocarcinoma: A Multicentre Study

Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.

Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma.